Raymond James downgraded Tandem Diabetes to Market Perform from Outperform without a price target.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TNDM:
- Tandem Diabetes down 5% after FDA approves Medtronic’s MiniMed 780G
- Tandem Diabetes Care announces publication of meta-analysis of Control-IQ trials
- Piper wonders if Medtronic’s 780G will be delayed further by FDA inspections
- Tandem Diabetes initiated with a Neutral at UBS
- Tandem Diabetes initiated with a Neutral at UBS